| Abstract | Virtually all cases of cervical cancer and its precursor intra-epithelial lesions are a result of infection with one or other of a subset of genital human papillomaviruses (HPVs), suggesting that prevention of HPV infection by prophylactic vaccination would be a highly effective anticancer strategy. Two HPV L1 virus-like particle vaccines have been developed, a quadrivalent HPV16/18/6/11 product and a bivalent HPV16/18 product; both have been shown to be highly immunogenic with a good safety profile and 100% efficacy against HPV16/18-related high-grade cervical intra-epithelial neoplasia (CIN2/3), implying that they will be effective at preventing HPV16/18-related cervical cancer. |
| Authors | M Stanley
(Affiliation: Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK. mas at mole.bio.cam.ac.uk)
|
| Journal | British journal of cancer
(Br J Cancer)
Vol. 96
Issue 9
Pg. 1320-3
(May 7 2007)
ISSN: 0007-0920 England |
| PMID | 17375045
(Publication Type: Journal Article, Review)
|
| Chemical References |
|
| Topics |
- Anus Neoplasms
(prevention & control, virology)
- Developed Countries
- Developing Countries
- Female
- Humans
- Incidence
- Papillomavirus Infections
(immunology, prevention & control)
- Papillomavirus Vaccines
- Uterine Cervical Neoplasms
(epidemiology, prevention & control, virology)
|
